Trishula is a privately held company solely dedicated to the development of TTX-030, a first-in-class anti-CD39 antibody, in collaboration with AbbVie. TTX-030 inhibits the activity of CD39, an ...

Trishula Therapeutics, Inc., a clinical stage, privately held biotechnology company, today reported final results from a Phase 1 trial of TTX-030, a potential first-in-class, anti-CD39 antibody ...

Trishula Therapeutics Initiates Phase 2 Trial of TTX-030, an Anti-CD39 Antibody, in First Line Metastatic Pancreatic Cancer Patients PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 9, 2023 ...

US-based biotechnology company Trishula Therapeutics has reported positive results from its Phase I clinical trial of TTX-030, an anti-CD39 antibody designed to treat first-line metastatic ...